Fig. 4

Decision Curve Analysis: Net benefit for noninvasive lymph node staging (NILS) model and the strategies sentinel lymph node biopsy (SLNB) for all and for none. The vertical grey line shows the cut-off 20% for N+ which in decision curve analysis terminology corresponds to accepting four false positive tests for each true positive test. The vertical red line represents the expected gain in net benefit if SLNB for all is replaced by the NILS model